Geron to Host a Virtual Investor Event in November
10/15/2021 - 04:05 PM
FOSTER CITY, Calif. --(BUSINESS WIRE)--
Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET . Topics to be covered at the event, include:
The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential of imetelstat, Geron’s first-in-class telomerase inhibitor.
Expansion opportunities for imetelstat into new indications and in combination with other drugs.
A live physician panel discussion and question-and-answer session with:
Dr. Swaminathan Iyer , Professor, Department of Lymphoma/Myeloma , Division of Cancer Medicine , The University of Texas MD Anderson Cancer Center , Houston, Texas
Dr. John Mascarenhas , Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York , New York
Prof. Uwe Platzbecker , Director, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, University Hospital , Leipzig, Germany
A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in myeloid hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211015005443/en/
Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com
Source: Geron Corporation
GERN Rankings
#3292 Ranked by Stock Gains
GERN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Foster City
About GERN
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.